GeoVax Labs Inc. and City of Hope entered into a license agreement granting GeoVax exclusive rights to further develop and commercialize COH04S1, a multi-antigenic SARS-CoV-2 investigational vaccine developed at City of Hope for immunocompromised patients.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe